Sentence examples for protracted continuous from inspiring English sources
S-1 is a fourth-generation oral fluoropyrimidine that was developed to mimic protracted continuous infusion of 5-fluorouracil (5-FU).
Regimens where 5-FU is administered as protracted continuous infusions may result in a more favourable toxicity profile including the frequency and severity of diarrhoea as compared to the Mayo regimen, where 5-FU is given as boluses on 5 consecutive days 4-weekly (de Gramont et al, 1997a).
There are several current and commonly used 5FU regimes ranging from protracted, continuous infusional 5FU delivery to bolus schedules.
It has been used with and without biomodulating agents such as leucovorin and methotrexate, alone as an intravenous bolus, by high-dose weekly 24-hour infusions, or by protracted continuous infusions which offer a higher response rate (33% vs 14%, P=0.0004) (de Gramont et al. 1997).
The first administration was matched to an induction treatment of octreotide (0.1 mg subcutaneous every 8 h) for 14 days; 5FU was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
Cisplatin was, in all cases, given at a dose of 60-100 mg/m2 infusion on day 1 in combination with capecitabine (1000 mg/m2 bid po on days 1-14, XP; n = 77), S-1 (40 mg/m2 bid po on days 1-21, SP; n = 97), docetaxel (75 mg/m2 iv on day 1, DP; n = 72), or 5-FU (800-1000 mg/m 2 iv on days 1-5 as a protracted continuous infusion, FP; n = 37).
For larger solutes, protracted or continuous online haemodiafiltration is more efficient.
Continuous protracted intravenous infusion (PVI) of 5-fluorouracil (5-FU) has a higher response rate, less frequent haematologic toxicity (mainly neutropenia), and more frequent hand foot syndrome (HFS) than bolus injection of 5-FU in patients with metastatic colorectal cancer (The Meta-Analysis Group in Cancer, 1998).
Infusional 5-FU was given as a protracted venous continuous infusion via a peripherally inserted central catheter or implantable device line by an ambulatory pump for 96 h (5 days week−1) at the first two dose levels, or for 168 h (7 days week−1) at the third dose level.
The use of an oral formulation of 5-FU allows protracted exposure without the inconvenience and cost of intravenous continuous-infusion regimens.
